Terns Pharmaceuticals, Inc.
TERN
Pozycja w akcjach
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Cena akcji
$52.95
Ostatnia synchronizacja: 2026-05-15
Kapitalizacja rynkowa
$4.77B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
529.61%
Kraj
US
Handel Terns Pharmaceuticals, Inc. (TERN)
Kategoria
Healthcare
EPS dla Terns Pharmaceuticals, Inc. (TERN)
EPS na dzień December 2025 TTM: $-1.03
Według najnowszych raportów finansowych i ceny akcji firmy Terns Pharmaceuticals, Inc., obecny EPS (TTM) wynosi $-1.03. Na koniec roku 2023 firma miała EPS w wysokości $-1.27, spadek w porównaniu do do EPS z roku 2022, który wynosił $-1.67.
Historia EPS dla Terns Pharmaceuticals, Inc. od 2018 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.03 | -8.04% |
| 2024 | $-1.12 | -11.81% |
| 2023 | $-1.27 | -23.95% |
| 2022 | $-1.67 | -15.66% |
| 2021 | $-1.98 | 22.98% |
| 2020 | $-1.61 | -41.24% |
| 2019 | $-2.74 | 270.27% |
| 2018 | $-0.74 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -1,781.55% |
US
|
|
| $-7.98 | 674.76% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,793.20% |
NL
|
